Open Access<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>
Author(s) -
Keitaro Shimozaki,
Yasutaka Sukawa,
Noriko Beppu,
Isao Kurihara,
Shigeaki Suzuki,
Ryuichi Mizuno,
Takeru Funakoshi,
Shinnosuke Ikemura,
Kai Tsugaru,
Kazuhiro Togasaki,
Kenta Kawasaki,
Kenro Hirata,
Hideyuki Hayashi,
Yasuo Hamamoto,
Hiromasa Takaishi,
Takanori Kanai
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s247554
Subject(s) - medicine , pembrolizumab , adverse effect , hazard ratio , nivolumab , atezolizumab , common terminology criteria for adverse events , renal cell carcinoma , confidence interval , lung cancer , oncology , cancer , retrospective cohort study , proportional hazards model , immunotherapy
Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in real-world practice.